How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?

Would you recommend concurrent chemoradiation or targeted therapy with lorlatinib?

Answer from: Medical Oncologist at Academic Institution

Stage IIIB encompasses T3-4N2 and T1-2N3, so I will assume that we are not going to consider a neo-adjuvant approach. Standard treatment for stage IIIB ALK+ NSCLC would be definitive concurrent chemo/RT given with curative intent. Reasonable chemo regimens would be weekly carboplatin plus paclitaxel...

Comments

Medical Oncologist at University of Illinois College of Medicine at Chicago
Appreciate this response, @Greg and agree with you...

Medical Oncologist at University of Michigan Medical School
Excellent thought, @Frank. We have not been using ...

Medical Oncologist at McLaren Health Care
Thank you so much for your response, @Gregory P. K...

Please select the option that best describes you:

How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?

Related Questions